Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.

COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older in China. Eligible participants were enrolled, the ratio of candidate vaccine and placebo within each dose group was 3:1 (phase 1) or 5:1 (phase 2). From August 28, 2020, 168 participants were sequentially enrolled and randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 28 days or 0, 14, 28 days in phase 1 trial. From November 18, 2020, 960 participants were randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 21 days or 0, 14, 28 days in phase 2 trial. The most common solicited injection site adverse reaction within 7 days in both trials was pain. The most common solicited systematic adverse reactions within 7 days were fatigue, cough, sore throat, fever and headache. ELISA antibodies and neutralising antibodies increased at 14 days, and peaked at 28 days (phase 1) or 30 days (phase 2) after the last dose vaccination. The GMTs of neutralising antibody against live SARS-CoV-2 at 28 days or 30 days after the last dose vaccination were highest in the adult high dose group (0, 14, 28 days), with 102.9 (95% CI 61.9-171.2) and 102.6 (95% CI 75.2-140.1) in phase 1 and phase 2 trials, respectively. Specific T-cell response peaked at 14 days after the last dose vaccination in phase 1 trial. This vaccine is safe, and induced significant immune responses after three doses of vaccination.

A Thermally and Chemically Stable Copper(II) Metal-Organic Framework with High Performance for Gas Adsorption and Separation.

A versatile microporous metal-organic framework (MOF), {[Cu(TIA)]·1.5CH3OH}n (Cu-1), was successfully obtained via the solvothermal reaction of cuprous(II) salt with the bifunctional ligand 3-(1H-1,2,4-triazol-1-yl)isophthalic acid. Single-crystal X-ray diffraction studies indicate that Cu-1 contains an apo three-dimensional skeleton and two types of one-dimensional channels. The framework of Cu-1 has excellent acid-alkali resistance and thermal stability, which is stable in a pH = 2-13 aqueous solution and an 260 °C air environment. In addition, the microporous copper MOF shows very high uptakes of CO2 (180 cm3·g-1) and C2H2 (113 cm3·g-1) at 273 K and displays excellent adsorption selectivity for small molecular gases. The ideal adsorbed solution theory selectivity values for C2H2/C2H4, CO2/CH4, and CO2/N2 are 2, 9, and 22 at 298 K, respectively. At the same time, breakthrough experiments for CO2/CH4, CO2/N2, and C2H2/C2H4 were further conducted to verify the efficient separation performances.

A Zn(ii) metal-organic framework based on bimetallic paddle wheels as a luminescence indicator for carcinogenic organic pollutants: phthalate esters.

Based on the multifunctional ligand 3-(1H-1,2,4-triazol-1-yl)isophthalic acid (H2TIA), a three-dimensional coordination polymer, namely {[Zn(TIA)]·DMA} n (Zn-1) was synthesized solvothermally. Single-crystal X-ray diffraction analyses confirmed that Zn-1 is a 3D framework composed of binuclear Zn2 paddle wheels with one-dimensional channels long the a direction. Further topological analyses revealed that MOF Zn-1 existed as a (3,6)-connected rtl binodal net {4·62}2{42·610·83}. Furthermore, the luminescence explorations indicate that complex Zn-1 is the first MOF for luminescent probing of phthalate esters (carcinogenic organic pollutants) with a high quenching-efficiency constant and low fluorescence-detection limit.